GT Biopharma Files 8-K for Material Agreement
Ticker: GTBP · Form: 8-K · Filed: 2026-04-07T07:05:14-04:00
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
GT Biopharma just signed a big deal, filing an 8-K on 4/7/26.
AI Summary
GT Biopharma, Inc. filed an 8-K on April 7, 2026, reporting the entry into a material definitive agreement on April 3, 2026. The filing also includes financial statements and exhibits related to this agreement.
Why It Matters
This filing indicates a significant new contract or partnership for GT Biopharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks depending on the nature of the agreement.
Key Players & Entities
- GT Biopharma, Inc. (company) — Filer
- 0000109657 (company) — CIK
- 2026-04-07 (date) — Filing Date
- 2026-04-03 (date) — Period of Report
- Item 1.01 (document_section) — Entry into a Material Definitive Agreement
- Item 9.01 (document_section) — Financial Statements and Exhibits
FAQ
What is the nature of the material definitive agreement entered into by GT Biopharma?
The filing does not specify the details of the material definitive agreement, only that one was entered into on April 3, 2026.
When did GT Biopharma file this 8-K report?
GT Biopharma filed this 8-K report on April 7, 2026.
What items are covered in this 8-K filing?
This 8-K filing covers Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
What is GT Biopharma's CIK number?
GT Biopharma's CIK number is 0000109657.
Where is GT Biopharma's business address listed?
GT Biopharma's business address is listed as 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2026-04-07 07:05:14
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
- $3.8 million — urces, provides for up to approximately $3.8 million over the course of three years borne by
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 176KB
- ex10-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-26-015413.txt ( ) — 418KB
- gtbp-20260403.xsd (EX-101.SCH) — 3KB
- gtbp-20260403_lab.xml (EX-101.LAB) — 33KB
- gtbp-20260403_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: April 7, 2026 By: /s/ Alan Urban Alan Urban Chief Financial Officer